Bioxytran (OTCQB: BIXT) has announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with laboratory-confirmed acute viral infection.
According to Bioxytran, the study design, endpoints, and duration confirmed an earlier randomized, placebo-controlled Phase 2 trial, which demonstrated statistically significant reductions in viral load by day seven, early clearance as soon as day three, and no observed viral rebounds during a 14-day post-treatment observation period.
In a statement, Dr. Leslie Ajayi, CMO of Bioxytran, commented, “The study design of seven days reflects real-world applications for treating acute viral diseases, with the objective of demonstrating a statistically meaningful reduction in viral load by day seven. The results demonstrate that viral clearance occurred more rapidly than anticipated, with a significant proportion of treated subjects achieving viral non-detection by day three and complete clearance by day seven.”
Based on these results, Bioxytran plans to advance regulatory discussions to support late-stage clinical development and evaluate ProLectin-M across additional viral indications consistent with its broad-spectrum antiviral profile
